Skip to content

Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)

Evaluation of the Neurologic Assessment in Pediatric Neuro-Oncology (pNANO)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06981156
Enrollment
252
Registered
2025-05-20
Start date
2025-05-13
Completion date
2027-01-01
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Brain Tumor, Pediatric Spine Tumor

Brief summary

This study aims to investigate a neurologic exam scale to provide an objective and more standard way to assess tumor response in pediatric patients with brain and spinal cord tumors.

Detailed description

This study is designed to evaluate inter-observer variability of the pNANO scale when implemented during routine clinic visits for pediatric brain and spine tumor patients. Typically, during a routine clinic visit for patients with pediatric brain and spine tumors, a neurological examination is completed and documented by a provider in clinic notes under the section 'Physical examination', sub-heading 'Neurologic examination.' For this study, every participant will have neurologic examinations performed by 2 or 3 (if feasible), separate providers on the same day (patient's scheduled provider and one or two additional providers from the Study Team), during a scheduled, routine clinic visit(s). To allow for potential significant discrepancies in exams between two providers, if feasible, a third provider will complete an examination at each visit. Each provider will independently perform the neurologic examination and will document the findings on the pNANO scale scorecard. Each provider will also record the amount of time it took to complete their neurologic examination. The providers will not communicate with each other about the findings and will be completely blinded to each other's evaluations. The pNANO scale will be completed at a second clinic visit, between 1-6 months out from the initial assessment. Telemedicine visit evaluations will be allowed for 20% of patients enrolled on study to assess if this scale is feasible via telemedicine. For telemedicine visits, one provider will need to be in clinic to complete the first examination and the second provider will be virtual to complete the second examination on the same day. A third provider would need to be in clinic to complete an examination. For the second evaluation 1-6 months after the first, the same will apply, one or two providers in clinic to complete the first examination while the second/third provider will be virtual. Providers can include physicians and advanced practice providers of any subspecialty: neurology, hematology-oncology, radiation oncology, neurosurgery, physical medicine and rehabilitation.

Interventions

DIAGNOSTIC_TESTpNANO Assessment

pNANO assesses patient gait, strength, cerebellar function, visual fields, visual acuity, facial strength, level of consciousness, extraocular movement, dysarthria, and dysphagia The patient will be assessed by 2-3 different clinicians during each of 2 visits.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* greater than or equal to 1 year old * must be seen in the pediatric clinic * Radiographic or histologic confirmation of a brain or spine tumor at the time of initial diagnosis * Patient or parent/guardian must be able to understand the consent and be willing to sign a written informed consent document according to institutional guidelines.

Exclusion criteria

* none specified

Design outcomes

Primary

MeasureTime frameDescription
Inter-observer Variability in pNANO Scores: Difference in Mean Cumulative ScoresVisit 1 (baseline), Visit 2 (up to 6 months)The Pediatric Neurologic Assessment in Neuro-Oncology (pNANO) is scored in multiple domains: - strength, level of consciousness, and gait domains (each individually scored 0-3) * facial strength, cerebellar function, visual fields, extraocular movements, dysphagia, and dysarthria domains (each individually scored 0-2) * visual acuity domain scored from 0-1 If summed, cumulative scores range from 0 (normal) to 22 (inability to function in each relevant domain) Investigators will explore variability across all domains.

Secondary

MeasureTime frameDescription
Feasibility: Clinical Exams that may correlate with pNANO scoresVisit 1 (baseline), Visit 2 (up to 6 months)Investigators will explore whether pNANO scores (individual domains or cumulative scores) correlate with clinical exams.
Feasibility: Inter-observer variability of pNANO scores between in clinic visits and Telemedicine reported as Difference in Mean Cumulative ScoresVisit 1 (baseline), Visit 2 (up to 6 months)A subset of participants (approximately 20%) will be assessed remotely to study any impact telemedicine has on pNANO scoring. If summed, cumulative scores range from 0 (normal) to 22 (inability to function in each relevant domain). Investigators will explore variability across all domains.

Countries

United States

Contacts

CONTACTCancer Connect
clinicaltrials@cancer.wisc.edu800-622-8922
PRINCIPAL_INVESTIGATORAustin Stuckert, MD

UW School of Medicine and Public Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026